Testing a new DNA vaccine for Alzheimer's disease
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
This study is testing a new DNA vaccine that aims to help your immune system fight a protein linked to Alzheimer's disease, and it's looking for volunteers to see how safe it is and how well it works in creating a protective response.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Institute for Molecular Medicine NIH-funded |
| Lab location | 1 site (Huntington Beach, United States) |
| Project ID | NIH-11053526 on NIH RePORTER |
What this research studies
This research investigates the safety, tolerability, and immune response of a novel DNA vaccine designed to target amyloid-beta, a protein associated with Alzheimer's disease. Participants will receive the vaccine to assess how well it can stimulate the immune system to produce antibodies against amyloid-beta, potentially preventing or slowing the progression of Alzheimer's. The study will involve monitoring participants for any side effects and measuring their immune responses over time. This approach aims to provide a more practical and cost-effective preventive measure compared to existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals in the early stages of Alzheimer's disease who are looking for preventive treatment options.
Not a fit: Patients with advanced Alzheimer's disease or those who do not have any signs of cognitive decline may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new preventive treatment for Alzheimer's disease that is easier to administer than current therapies.
How similar studies have performed: Previous studies with similar vaccine approaches have shown promise, but this specific DNA vaccine is a novel approach in the field.
Where this research is happening
Huntington Beach, United States
- Institute for Molecular Medicine — Huntington Beach, United States (Active)
Researchers
- Principal investigator: Agadjanyan, Michael G — Institute for Molecular Medicine
- Study coordinator: Agadjanyan, Michael G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.